5 Stocks Pushing The Health Services Industry Higher

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Two out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 40 points (0.3%) at 13,114 as of Friday, Dec. 7, 2012, 11:49 AM ET. The NYSE advances/declines ratio sits at 1,438 issues advancing vs. 1,420 declining with 156 unchanged.

The Health Services industry currently sits up 0.8% versus the S&P 500, which is up 0.1%. Top gainers within the industry include WellCare Health Plans ( WCG), up 3.9%, HCA Holdings ( HCA), up 2.1% and Humana ( HUM), up 1.5%. A company within the industry that fell today was Intuitive Surgical ( ISRG), up 0.8%.

TheStreet Ratings group would like to highlight 5 stocks pushing the industry higher today:

5. ResMed ( RMD) is one of the companies pushing the Health Services industry higher today. As of noon trading, ResMed is up $0.42 (1.0%) to $41.56 on light volume Thus far, 204,021 shares of ResMed exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $41.22-$41.66 after having opened the day at $41.31 as compared to the previous trading day's close of $41.13.

ResMed Inc., through its subsidiaries, engages in the development, manufacture, and distribution of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. ResMed has a market cap of $5.8 billion and is part of the health care sector. The company has a P/E ratio of 21.8, above the S&P 500 P/E ratio of 17.7. Shares are up 61.9% year to date as of the close of trading on Thursday. Currently there are 4 analysts that rate ResMed a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates ResMed as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full ResMed Ratings Report now.

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

If you liked this article you might like

Here's Why This Rally Is Sustainable: Cramer's 'Mad Money' Recap (Tuesday 1/24/17)

ResMed: Cramer's Top Takeaways

Why CarMax and Garmin Could Be Prime Candidates for a Short Squeeze

Why a Massive Short Squeeze Could Send These 4 Stocks Into Orbit

ResMed (RMD) Stock Sharply Lower After Q1 Results Miss Estimates